VTGN
Vistagen Therapeutics, Inc. Common Stock
stockNASDAQ
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.17 | 2026-11-03 | +9.11% | 3.281 |
| 1M | 0.24 | 2026-10-09 | -22.36% | 2.845 |
| 3M | 0.26 | 2026-08-10 | -30.52% | 1.215 |
| 6M | 0.67 | 2026-05-11 | -72.79% | 0.926 |
| 1Y | 3.98 | 2025-11-10 | -95.39% | 1.556 |
| 2Y | 3.02 | 2024-11-11 | -93.93% | — |
| 5Y | 67.50 | 2021-11-10 | -99.73% | 1.774 |
Vistagen Therapeutics, Inc. Common Stock (NASDAQ:VTGN) stock price today is $0.18, and today's volume is 273,676. VTGN is down 0.597% today. The 30 day average volume is 1.02M. VTGN market cap is $8.13M with 44.38M shares outstanding.